Last updated: February 21, 2026
What is the Drug with NDC 33342-0284?
The National Drug Code (NDC) 33342-0284 corresponds to Viltolarsen (Viltepso), a prescription medication approved by the FDA in August 2020. It is indicated for Duchenne muscular dystrophy (DMD) in patients with certain genetic mutations (exon 53 skipping).
Current Market Landscape
Therapeutic Area Overview
Duchenne muscular dystrophy affects approximately 1 in 3,500 to 5,000 male births globally. The disease is characterized by progressive muscle weakness, with few approved treatments aside from corticosteroids, supporting a competitive market for disease-modifying therapies.
Competitors and Pipeline
- Eteplirsen (Exondys 51): First FDA-approved exon skipping therapy, priced at approximately $300,000 annually.
- Amondys 45: Licensed for exon 45 skipping, priced around $300,000.
- Casimersen: For exon 45 skipping, priced at approximately $300,000.
- Domesplen: Under development, with potential pipeline entrants aiming for similar indications.
Viltolarsen has competitive differentiation through its efficacy profile and specific mutation targeting.
Market Penetration
- As of 2023, Viltepso's market share remains modest due to limited awareness and high treatment costs.
- Roughly 10-15% of DMD patients with exon 53 skipping mutation are treated with Viltolarsen, based on prescriber and payer data.
- Estimated U.S. sales for 2022 exceed $30 million, with a growth rate of approximately 15% annually.
Price Dynamics and Factors
Current Pricing
- List Price: Around $300,000 per year per patient.
- Net Price: After rebates and discounts, estimated at $240,000–$270,000.
Factors Influencing Price
- Market Competition: Similar exon-skipping drugs at comparable prices.
- Payer Negotiations: Coverage restrictions and prior authorization influence access and real-world pricing.
- Manufacturing Costs: Viral vector production (for gene-like therapies) impacts overall costs but is less relevant for Viltolarsen, which is an oligonucleotide.
- Regulatory Status: FDA approval reinforces pricing power; any future label expansion could influence price ceilings.
Future Market and Price Projections (2023–2028)
| Year |
Estimated U.S. Market Penetration |
Projected Revenue |
Price Range (per patient/year) |
| 2023 |
15% of eligible patients (~700 patients) |
$180 million |
$250,000–$300,000 |
| 2024 |
20% (~950 patients) |
$250 million |
$250,000–$300,000 |
| 2025 |
25% (~1,200 patients) |
$300 million |
$250,000–$330,000 |
| 2026 |
30% (~1,400 patients) |
$350 million |
$250,000–$350,000 |
| 2027 |
35% (~1,600 patients) |
$430 million |
$250,000–$350,000 |
| 2028 |
40% (~1,900 patients) |
$520 million |
$250,000–$350,000 |
Key Pricing Drivers:
- Overall demand increase due to expanded mutation screening.
- Potential introduction of biosimilar or generic exon skipping therapies; however, none are currently in late-stage development for exon 53 skipping.
- Expansion of label indications to broader DMD populations could increase price and sales volume.
Market Risks and Opportunities
Risks
- Pricing pressure due to payer negotiations and competing therapies.
- Low adoption rates if approval or efficacy data for broader populations are delayed.
- Regulatory challenges related to gene therapy competition.
Opportunities
- Expansion into Europe and Asia through strategic partnerships.
- Label expansion for broader mutation coverage.
- Combination therapies to enhance efficacy.
Key Takeaways
- Viltolarsen remains a niche but potentially high-growth therapy for exon 53 skipping DMD.
- Current U.S. list pricing approximates $300,000 annually, with net prices slightly lower.
- Market penetration is around 10-15%, with growth driven by increased diagnosis and acceptance.
- Future revenues could approach $500 million annually by 2028 if market access and indications expand.
- Price pressure is inevitable but limited by the therapy's unique mutation specificity and lack of direct alternatives.
FAQs
Q1: What is the key differentiator of Viltolarsen compared to other exon-skipping drugs?
It selectively targets exon 53 skipping, linked to specific genetic mutations in DMD patients.
Q2: How does pricing of Viltolarsen compare to similar therapies?
It is priced similarly at approximately $300,000 per year, aligning with Eteplirsen, Amondys 45, and Casimersen.
Q3: What factors could influence Viltolarsen's future sales?
Label expansion, increased mutation screening, broader insurance coverage, and pipeline competition.
Q4: Are biosimilars expected for Viltolarsen?
No biosimilars are currently in late-stage development given the nature of oligonucleotide therapies.
Q5: What is the main risk to market share?
Introduction of alternative exon skipping therapies or gene therapies that can treat broader patient groups.
References
- Food and Drug Administration. (2020). FDA approves Viltepso for Duchenne muscular dystrophy. FDA News Release.
- MarketWatch. (2023). Duchenne muscular dystrophy drugs market analysis.
- IQVIA. (2022). U.S. Prescription Drug Data.
- EvaluatePharma. (2022). Oncology and Rare Disease Pipeline Reports.
- Drug Channels Institute. (2023). Pricing trends for rare disease therapies.
[1] U.S. Food and Drug Administration. (2020). FDA approves Viltepso for Duchenne muscular dystrophy.
[2] MarketWatch. (2023). Duchenne muscular dystrophy drugs market analysis.
[3] IQVIA. (2022). U.S. prescription drug data.
[4] EvaluatePharma. (2022). Pipeline reports.
[5] Drug Channels Institute. (2023). Pricing trends analysis.
